Keyphrases
Cell Cycle Control
100%
Therapy-resistant
100%
Endocrine Therapy
100%
Resistant Breast Cancer
100%
Estrogen Receptor
60%
Tumor
40%
PD0332991
40%
Estrogen Receptor-positive Breast Cancer
40%
Transcriptional Repression
20%
Hormone Refractory
20%
Phosphorylation
20%
Therapeutic Potential
20%
Cell Population
20%
Acquired Resistance
20%
Clinical Utility
20%
Cyclin-dependent Kinase 4 (CDK4)
20%
Cyclin D1 (CCND1)
20%
Therapeutic Intervention
20%
Hormone Therapy
20%
Cell Cycle Progression
20%
Treatment Refractory
20%
New Therapeutics
20%
Cellular Senescence
20%
Luminal Breast Cancer
20%
Kinase Activity
20%
Transcriptional Control
20%
Highly Selective
20%
Functional State
20%
Estrogen Receptor Antagonist
20%
Cell Cycle Arrest
20%
Resistance to Therapy
20%
Activity State
20%
Differential Susceptibility
20%
Cyclin D
20%
Retinoblastoma Protein
20%
Poor Response
20%
Antihormone Therapy
20%
Efficient Ablation
20%
Stable Cell Line
20%
Common Node
20%
Cytostatic Therapy
20%
Gene Signature
20%
Medicine and Dentistry
Breast Cancer
100%
Hormone Therapy
100%
Cell Cycle Regulation
100%
Estrogen Receptor
50%
Estrogen Receptor Positive Breast Cancer
33%
Tumor
33%
Retinoblastoma
16%
Phosphotransferase
16%
Targeted Therapy
16%
Cell Population
16%
Cell Cycle Progression
16%
Cyclin D1
16%
Cell Cycle Arrest
16%
Gene Expression Profiling
16%
Cell Cycle Checkpoint
16%
Estrogen Receptor Antagonist
16%
Cyclin D
16%
Cellular Senescence
16%
Luminal B Breast Cancer
16%
Tumor Suppressor Protein
16%
CDK4/6 Inhibitor
16%
Cytostatic
16%
Biochemistry, Genetics and Molecular Biology
Cell Cycle Regulation
100%
Estrogen Receptor
100%
Gene Expression Profiling
16%
Tumor Suppressor Protein
16%
E2F
16%
Cell Cycle Progression
16%
Cell Cycle Arrest
16%
Receptor Antagonist
16%
Cyclin D
16%
Cell Cycle Checkpoint
16%
Phosphotransferase
16%
Kinase
16%
Cyclin D1
16%
Retinoblastoma
16%
Targeted Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Breast Cancer
100%
Estrogen Receptor
50%
Estrogen Receptor Positive Breast Cancer
33%
Tumor Suppressor Protein
16%
Phosphotransferase
16%
Cyclin D1
16%
Estrogen Receptor Antagonist
16%
Cyclin D
16%
Luminal B Breast Cancer
16%
Retinoblastoma
16%
Cytostatic
16%